SCHEMBL6017475

SCHEMBL6017475

Cc1noc(NS(=O)(=O)c2ccc(NC(=O)CCC(=O)O)cc2)c1C

nearest known ligand 0.76

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 2/20 0.71
▸ GAA P10253 1/20 0.70
▸ ALDH1A1 P00352 5/20 0.66
▸ CYP3A4 P08684 1/20 0.66
▸ CYP2C9 P11712 1/20 0.66
▸ TSHR P16473 1/20 0.66
▸ CYP2C19 P33261 1/20 0.66
▸ MAPT P10636 3/20 0.65
▸ MEN1 O00255 2/20 0.65
▸ KMT2A Q03164 2/20 0.65
▸ SMN1; SMN2 Q16637 2/20 0.65
▸ L3MBTL1 Q9Y468 1/20 0.65
▸ TP53 P04637 1/20 0.64
▸ RXFP1 Q9HBX9 2/20 0.64
▸ P2RY1 P47900 1/20 0.63
▸ THRB P10828 2/20 0.63
▸ POLB P06746 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7857278 0.83 TP53 (0.72) GAAMAPTMEN1KMT2AL3MBTL1
SCHEMBL12262674 0.82 ALDH1A1 (0.85) HTTGAAALDH1A1CYP3A4CYP2C9
SCHEMBL12010930 0.81 HSP90AA1 (0.83) GAAALDH1A1TSHRMAPTMEN1
SCHEMBL13390864 0.80 TP53 (0.68) GAAALDH1A1MAPTMEN1KMT2A
SCHEMBL10031585 0.79 KDM4E (0.67) GAAMAPTMEN1KMT2AL3MBTL1
SCHEMBL17689189 0.77 TP53 (0.81) ALDH1A1CYP3A4CYP2C9MAPTMEN1
SCHEMBL7850007 0.77 EDNRA (0.81) ALDH1A1CYP2C9TSHRCYP2C19MEN1
SCHEMBL21654417 0.76 POLB (0.85) GAAMAPTMEN1KMT2AL3MBTL1
SCHEMBL12262637 0.76 MAPT (0.86) HTTGAAALDH1A1CYP3A4CYP2C9
SCHEMBL7716850 0.76 EDNRA (1.00) CYP2C9TSHRCYP2C19MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0973552-B1 IMPROVEMENTS IN OR RELATING TO DIAGNOSTIC/THERAPEUTIC AGENTS AMERSHAM HEALTH AS (NO) 2006-03-01 — — EP disclosed
US-20040141922-A1 Diagnostic/therapeutic agents NYCOMED IMAGING AS 2004-07-22 — — US disclosed
US-20020102215-A1 Diagnostic/therapeutic agents NYCOMED IMAGING AS 2002-08-01 — — US disclosed
US-6264917-B1 MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT NYCOMED IMAGING AS (NO) 2001-07-24 — — US disclosed
US-6261537-B1 TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES NYCOMED IMAGING AS (NO) 2001-07-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040141922-A1 Diagnostic/therapeutic agents BID, FUS, FABP1 HTT 1890/4885GAA 2714/4885ALDH1A1 4549/4885
US-20020102215-A1 Diagnostic/therapeutic agents BID, FUS, FABP1 HTT 2183/4885GAA 2444/4885ALDH1A1 4459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback